Supplement

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19



Supplemental figure 1: Immunoblot with examples of non-detectable (-) [LCS01], below cutoff (+/-) [LCS02], with cutoff intensity (+) [LCS10], above cutoff (++) [LCS12], and very strong intensity (+++) [LCS16] NP OC43 antibodies.



Supplemental figure 2: Immunoblot dilution series for densitometric antibody measurement. Raw intensity values of 7 different antibodies are presented (NP229E, NPNL63, NPOC43, NPHKU1, NPSARS2, RBDSARS-2, S1SARS-2) for 7 dilution steps. Cut-off level is relatively stable, raw intensity values are approximately linear, therefore densitometric antibody levels can be analyzed quantitatively.



Supplemental figure 3: Association of HCoV OC43 antibody levels with known risk factors for COVID-19 severity. Black dots indicate male patients, red dots female patients. Crosses denote fatal cases. There was no significant difference regarding HCoV OC43-specifc antibody levels regarding sex, age or BMI in the validation cohort.



Supplemental figure 4: Proportion of ordinal HCoV antibody levels from COVID-19 patients with and without critical disease for the full validation cohort (including outpatients). COVID-19 patients with critical disease presented low antibody levels more frequently than patients without critical disease. This difference was most pronounced for HoC OC43 (odds ratio 2.16 [95% CI 1.15 - 4.07]).



Supplemental Figure 5: Relative antibody levels against HCoV OC43, HKU1, NL63 and 229E. COVID-19 inpatients from the ICU group presented lower median NPOC43 levels than patients from the non-ICU group (p=0.038). Median NPOC43 levels for outpatients were located between corresponding levels of non-ICU and ICU patients (no significant differences in both directions).



Supplemental Figure 6: Boxplots of SARS-CoV-2 relative antibody levels for outpatients, patients with severe/moderate disease (non-ICU group) and critical disease (ICU group). Median antibody levels were significantly higher for inpatients (non-ICU/ICU) than for outpatients (p<0.0001) for NP SARS2, RBD SARS2 and S1 SARS2. It has to be taken into account that median time point of sample collection for outpatients was 5 days after symptom onset and 8 days for inpatients, respectively.



Supplemental figure 7: Correlation of antibody levels for S1SARS2 measured by ELISA and Immunoblot. ELISA and Immunoblot values are highly correlated (correlation coefficient 0.84; p<0.001). Therefore antibody levels determined by Immunoblot can be analyzed quantitatively.



Supplemental figure 8: Scatterplot of NPOC43 and S1SARS2 antibody levels for patients with NPOC43 antibodies. There is no significant correlation between NPOC43 and S1SARS2 antibody levels (p=0.33). There is no evidence for cross-reaction between NPOC43 and S1SARS2 on the antibody level.

248 COVID patients			
106 outpatients			
142 inpatients		OC43 negative (-)	79% ICU
			15 ICU 4 non-ICU
89	male inpatients	OC43 below (+/-) or with cutoff (+)	60% ICU
			34 ICU 23 non-ICU
		OC43 positive (++) or strong positive (+++)	38% ICU
			5 ICU 8 non-ICU
		OC43 negative (-)	62% ICU
			8 ICU 5 non-ICU
53	female inpatients	OC43 below (+/-) or with cutoff (+)	34% ICU
			12 ICU 23 non-ICU
		OC43 positive (++) or strong positive (+++)	0% ICU
			0 ICU 5 non-ICU

Supplemental table 1: COVID-19 inpatient risk stratification by sex and OC43 serostatus. Multivariate analysis of 142 patients identified sex and OC43 serostatus as strongest predictors for critical disease. Age and BMI did not reach statistical significance in this cohort. 90% of males in this cohort were 42 years or older; 90% of females in this cohort were 39 years or older. For this reason, this table could be applied for inpatients aged 40 years or older to estimate the risk of critical disease. For example, an OC43 negative female inpatient would have an estimated risk of 62%.